{"schema_version":"1.0","type":"article","title":"Pfizer 22.6 億美元收購 Trillium 後，maplirpacept 停止開發，CD47 還剩哪四條路？","url":"https://drugnews.com.tw/articles/2026-09-14-cd47-after-pipeline-exits.html","markdown_url":"https://drugnews.com.tw/articles/2026-09-14-cd47-after-pipeline-exits.md","lang":"zh-Hant","date":"2026-09-14","publish_at":"2026-09-14T08:00:00+08:00","updated_at":"2026-09-14","category":"商業分析系列","topic":"商業分析系列","tags":["CD47","Pfizer","Gilead","ALX Oncology","巨噬細胞","生技投資"],"summary":"三種不同退出不能被壓成一次 class verdict；CD47 的剩餘價值要分開看組合、分層、減毒設計與人體證據。","key_points":[],"facts":[],"sections":[],"references":[],"images":[{"alt":"圖 1｜Pfizer 停止 maplirpacept 開發後，CD47 剩餘四種可投資路線","url":"https://drugnews.com.tw/assets/articles/cd47-after-pipeline-exits/01_%E5%B0%81%E9%9D%A2_CD47%E4%B8%8D%E6%98%AF%E5%9C%98%E6%BB%85%E6%98%AF%E8%B7%AF%E7%B7%9A%E6%B7%98%E6%B1%B0.png"},{"alt":"圖 2｜Magrolimab、maplirpacept、evorpacept 的退出理由不能混寫","url":"https://drugnews.com.tw/assets/articles/cd47-after-pipeline-exits/02_%E9%80%80%E5%87%BA%E8%A1%A8_%E4%B8%89%E7%A8%AE%E5%A4%B1%E6%95%97%E4%B8%8D%E8%83%BD%E6%B7%B7%E6%88%90%E4%B8%80%E7%A8%AE.png"},{"alt":"圖 3｜CD47 剩餘四張牌：組合、分層、減毒、人體證據","url":"https://drugnews.com.tw/assets/articles/cd47-after-pipeline-exits/03_%E5%89%A9%E9%A4%98%E5%9B%9B%E7%89%8C_%E7%B5%84%E5%90%88%E5%88%86%E5%B1%A4%E6%B8%9B%E6%AF%92%E4%BA%BA%E9%AB%94%E8%AD%89%E6%93%9A.png"},{"alt":"圖 4｜CD47 投資檢查表：先看分母、終點與證據層級","url":"https://drugnews.com.tw/assets/articles/cd47-after-pipeline-exits/04_%E6%8A%95%E8%B3%87%E6%AA%A2%E6%9F%A5%E8%A1%A8_%E5%85%88%E7%9C%8B%E5%88%86%E6%AF%8D%E5%86%8D%E7%9C%8BORR.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/cd47-after-pipeline-exits/01_%E5%B0%81%E9%9D%A2_CD47%E4%B8%8D%E6%98%AF%E5%9C%98%E6%BB%85%E6%98%AF%E8%B7%AF%E7%B7%9A%E6%B7%98%E6%B1%B0.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-09-14）。Pfizer 22.6 億美元收購 Trillium 後，maplirpacept 停止開發，CD47 還剩哪四條路？。https://drugnews.com.tw/articles/2026-09-14-cd47-after-pipeline-exits.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}